Magnetic resonance imaging striatal volumes: A biomarker for clinical trials in Huntington's disease

An abundance of research shows that magnetic resonance imaging (MRI) striatal volumes decrease long before diagnosis of Huntington's disease (HD) and closely track disease progression. Additional research indicates that these volumetric measures meet important criteria for a biomarker that can...

Full description

Saved in:
Bibliographic Details
Published in:Movement disorders 2014-09, Vol.29 (11), p.1429-1433
Main Author: Aylward, Elizabeth H.
Format: Article
Language:English
Subjects:
biomarker
Biomarkers - metabolism
Clinical Trials as Topic - methods
Corpus Striatum - pathology
Humans
Huntington Disease - metabolism
Huntington Disease - pathology
Huntington Disease - therapy
Huntington's disease
Magnetic Resonance Imaging
Movement disorders
MRI
striatal volume
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An abundance of research shows that magnetic resonance imaging (MRI) striatal volumes decrease long before diagnosis of Huntington's disease (HD) and closely track disease progression. Additional research indicates that these volumetric measures meet important criteria for a biomarker that can be used in clinical trials: They are 1) objectively measureable; 2) able to predict known endpoints; and 3) associated with known mechanisms of pathology of the disease. Researchers should consider formal application to regulatory agencies for biomarker status of volumetric MRI striatal measures, because these measures are anticipated to contribute significantly in the assessment of treatment effectiveness in HD. © 2014 International Parkinson and Movement Disorder Society
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.26013